AMP Webinar: Comprehensive Tumor Characterization Using Augmented NGS
This online seminar will outline a target enrichment technology to improve next generation sequencing assays for cancer research.
This online seminar will outline a target enrichment technology to improve next generation sequencing assays for cancer research.
GenomeWeb: Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research This GenomeWeb seminar outlines a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. Presenters: Richard Chen, MD and Michael James Clark, PhD More Info: NGS is increasingly being used to support cancer clinical trials, translational [...]
NGS Best Practices for Developing Personalized Neoantigen Vaccines Precision medicine strategies have changed how the industry is approaching the development of cancer treatment vaccines, from targeting tumor-specific mutations to harnessing the power of the immune system. Advances in immuno-oncology research and next-generation sequencing (NGS) technologies has led to the discovery of a promising [...]
Labroots: Precision Genomics and Precision Medicine for Immuno Oncology Tumors often evade immune destruction by adapting and circumventing immune checkpoints to create resistance. This adaptive immunity can be reversed to stimulate the endogenous immune response. Extensive efforts using Immunotherapeutic approaches are currently being investigated for various cancer types to activate our immune system, [...]
Find the answers to the most complex biological questions, with augmented NGS Find the answers to the most complex biological questions, with augmented NGS Finding the answers to complex biological questions, requires a deeper understanding of cancer biology. Personalis ACE Cancer Exome and ACE Cancer Transcriptome features augmented DNA and RNA sequencing for [...]
Unlocking the potential of personalized neoantigen vaccines with ACE ImmunoID™ Cancer vaccine success has been limited, but neoantigen cancer vaccines are demonstrating considerable potential. Learn more about how Personalis can help you to accurately detect neoantigens to enable the development of safer, more effective vaccines.
Checkpoint inhibitors and modulators have shown great promise in the treatment of cancer, but response rates have been limited.
Precision Genomics for Precision Medicine: Examples in Immuno-Oncology Richard Chen, Personalis - Stanford Medicine Big Data | Precision Health 2016. Bringing together thought leaders in large-scale data analysis and technology to transform the way we diagnose, treat and prevent disease.